- Home
- AEM vs BMY Comparison
AEM vs BMY Comparison
Compare AEM & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEM | BMY |
|---|---|---|
| Founded | 1953 | 1887 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6B | 110.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEM | BMY |
|---|---|---|
| Price | $196.37 | $55.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $223.71 | $58.21 |
| AVG Volume (30 Days) | 3.0M | ★ 12.6M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | 0.84% | ★ 4.51% |
| EPS Growth | ★ 237.78 | N/A |
| EPS | ★ 6.84 | 2.97 |
| Revenue | $10,567,578,000.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $42.18 | $0.27 |
| Revenue Next Year | $19.44 | N/A |
| P/E Ratio | $27.89 | ★ $18.82 |
| Revenue Growth | ★ 35.16 | 1.26 |
| 52 Week Low | $92.11 | $42.52 |
| 52 Week High | $225.00 | $63.33 |
Technical Indicators
Market Signals| Indicator | AEM | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 58.59 |
| Support Level | $187.04 | $54.21 |
| Resistance Level | $225.00 | $56.12 |
| Average True Range (ATR) | 8.69 | 1.12 |
| MACD | -2.58 | -0.12 |
| Stochastic Oscillator | 24.58 | 68.53 |
Price Performance
Historical ComparisonAbout AEM Agnico Eagle Mines Limited
Agnico Eagle is a gold miner with mines in Canada, Mexico, Finland, and Australia. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines online in rapid succession in the following years. It merged with Kirkland Lake Gold in 2022, acquiring the Detour Lake and Macassa mines in Canada along with the high-grade, low-cost Fosterville mine in Australia. It sold around 3.4 million gold ounces in 2024 and had about 15 years of gold reserves at end 2024. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions and bought the remaining 50% of its Canadian Malartic mine along with the Wasamac project and other assets from Yamana Gold in 2023.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.